Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio Data from the phase Ib Beamion LUNG-1 trial selected for late-breaking oral presentation in the Presidential Symposium at WCLC on Monday, September 9. The U.S. FDA and China's CDE have granted...